MedPath

A prospective observational study of structure and visual field progression in open-angle glaucoma

Not Applicable
Conditions
Glaucoma
Registration Number
JPRN-UMIN000012411
Lead Sponsor
Santen Pharmaceutical CO., LTD.
Brief Summary

The analysis included 195 eyes of 115 patients [41 eyes in POAG (narrow) and 154 eyes in normal tension glaucoma (NTG)], 32 eyes in DH group, 10 eyes in migraine group, and 19 eyes in diabetic group. The mean IOP and mean MD of all groups at baseline were 13.3 plus or minus 2.2 mmHg and -6.4 plus or minus4.0 dB, respectively; the DH group had a greater proportion of NTG than the group without risk factors, but there was no significant difference in the degree of visual field impairment.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
119
Inclusion Criteria

Not provided

Exclusion Criteria

Subject who has a disease which considered inappropriate from safety perspective(severe cardiovascular/ respiratory/ hepatobiliary/ digestive/ urinary/ renal/ hematological/ endocrine/ immune disease, malignant tumor, etc.) The investigator, subinvestigator determined that the person is ineligible as study subject

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath